It is indisputable that COVID-19 virus interfered with the health status, education, socio economic impact on Sri Lanka and is threatening the entire world at present. Several vaccines are being developed; clinical trials are being performed aiming to eradicate the virus. The application of traditional medicinal plants as treatments of patients or as supportive therapies is a common topic being discussed today. In this review, we discuss the current situation of COVID-19 infection in Sri Lanka, pathogenesis of the entry of COVID-19 virus to human red blood cells, hematological complications, existing laboratory diagnosis methods. We discuss the properties of traditional Sri Lankan plant, Lantana camara and how its activities are useful to act against the fatal pathophysiology that may associate with COVID-19 infected and post COVID-19 infected blood. Furthermore, we create a platform to discuss the possibilities of using Lantana camara in the management of COVID-19 patients in future.

No abstract

Non-Hodgkin's lymphoma (NHL) is a varied set of lymphoproliferative disorders initiatingfrom B, T, or natural killer (NK) lymphocytes. Common treatments of NHL include chemotherapy regimens, radiotherapy, rituximab administration, transfusion of blood products and Peripheral blood stem cell transplantation. Recently, several targeted therapies have been approved or are in the later phase of clinical trials and molecular targeted therapy is considered as a key aspect of NHL. Successful treatment of lymphoma may result from the induction of specific antitumor immunity. Myeloid-derived suppressor cells (MDSC) are being investigated as a possible target in solid tumors and most of blood cancers to improve the effects of commonly used undergoing treatment. The anti-tumor immune response of a diseased person is inhibited by MDSC expansion, which restricts, cytokine secretion, T cell proliferation and the activation of regulatory T cells. In order to identify immunological therapeutic targets, it is critical to identify tumor-promoting factors. Since this environment is focus to low selective pressure for mutations, targeting the Tumor Microenvironment (TME) is a promising therapeutic option for Non-Hodgkin lymphoma. The features, distribution, roles, cellular reactions, and aiming MDSCs in Non-Hodgkin lymphoma are discussed in this review.